High plasma tumor necrosis factor (TNF)-α concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-α, interferon-γ, and melphalan

Critical Care Medicine

Volumn 24, Issue 5, 1996, Pages 765-770

  Zwaveling, Jan H ^b   Maring, Jan K ^b   Clarke, Fiona L ^a   Van Ginkel, Robert J ^b   Limburg, Pieter C ^b   Hoekstra, Harald J ^b   Schraffordt Koops, Heimen ^b   Girbes, Armand R J ^b  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Critical illness; Cytokines; Interferon; Melphalan; Perfusion, regional; Sepsis; Sepsis syndrome; Tumor necrosis factor ; Vascular surgery

Indexed keywords

DOPAMINE; HEPARIN; ISOFLURANE; MELPHALAN; MIDAZOLAM; NITROUS OXIDE; PROTAMINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SUFENTANIL; THIOPENTAL; TUMOR NECROSIS FACTOR ALPHA; VECURONIUM;

ADULT; AGED; ANESTHESIA INDUCTION; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COLLOID; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLUID THERAPY; HEMODYNAMICS; HISTOLOGY; HUMAN; HYPERTHERMIC THERAPY; INTENSIVE CARE UNIT; LIMB PERFUSION; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SOFT TISSUE TUMOR; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; EXTREMITIES; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTHERMIA, INDUCED; INTERFERON-GAMMA, RECOMBINANT; LINEAR MODELS; MALE; MELPHALAN; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029938137     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199605000-00007     Document Type: Article

References (32)

1. Rock CS, Lowry SF: Current research review. Tumor necrosis factor alpha. J Surg Res 1991; 51:434-445
2. Dofferhof ASM, Vellenga E, Limburg PC, et al: Tumour necrosis factor (cachectin) and other cytokines in septic shock: A review of the literature. Neth J Med 1991; 39:45-62
3. Schutze S, Machleidt T, Kronke M: Mechanisms of tumor necrosis factor action. Semin Oncol 1992; 2(Suppl 4):16-24
4. Beutler B, Cerami A: Cachectin: More than a tumor necrosis factor. N Engl J Med 1987; 316:379-385
5. Hesse DG, Tracey KJ, Fong Y, et al: Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166:147-153
6. Cannon JG, Tompkins RG, Gelfand JA, et al: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161:79-84
7. Glauser MP, Zanetti G, Baumgartner JD: Septic shock: Pathogenesis. Lancet 1991; 338:732-735
8. Hollenburg SM, Cunnion RE, Parrillo JE: The effect of tumor necrosis factor on vascular smooth muscle. Chest 1991; 100:1133-1137
9. Heard SO, Perkins MW, Fink MP: Tumor necrosis factor alpha causes myocardial depression in guinea pigs. Crit Care Med 1992; 20:523-527
10. Carey PD, Leeper-Woodford SK, Walsh CJ, et al: Delayed cyclo-oxygenase blockade reduces the neutrophil respiratory-burst and plasma tumor necrosis factor levels in sepsis induced acute lung injury. J Trauma 1991; 31:733-742
11. Dofferhof ASM, Bom VJJ, de Vries-Hospers HG, et al: Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992; 20: 185-199
12. Sullivan JS, Kilpatrick L, Costarino AT, et al: Correlation of plasma cytokine elevations with mortality rate in children with sepsis. J Pediatr 1992; 120:510-515
13. 2 and cachectin levels in adult respiratory distress syndrome and multiple-organ failure. Clin Biochem 1992; 25:55-60
14. Debets JMH, Kampmeijer R, van der Linden MPMH, et al: Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17:489-193
15. Suffredini AF, Fromm RE, Parker MM, et al: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321: 280-287
16. van der Poll T, Levi M, Buller HR, et al: Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174:729-732
17. van Deventer SJH, Buller HR, ten Cate JW, et al: Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-2526
18. van Hinsbergh VWM, Bauer KA, Kluft C, et al: Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1 and fibrin(ogen) degradation products. Blood 1990; 76:2284-2289
19. Lienard D, Ewalenko P, Delmotte JJ, et al: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:52-60
20. Creech O Jr, Krementz ET: Cancer chemotherapy by perfusion. Adv Cancer Res 1968; 6:111-147
21. Alexander C, Omlor G, Berberich R, et al: Rapid measurement of blood leakage during regional chemotherapy. Eur J Nucl Med 1993; 20:187-191
22. Murray JF, Matthay MA, Luce JM, et al: An expanded definition of adult respiratory distress syndrome. Am Rev Respir Dis 1988; 136:720-723
23. Baumgartner JD, Bula C, Vaney C, et al: A novel score for predicting the mortality of septic shock patients. Crit Care Med 1992; 20:953-960
24. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234:470-474
25. Kaplan KL: Methods for assessing activation of coagulation by contrast materials for catheters. Semin Hematol 1991; 28(Suppl 7):16-21
26. Tennenberg SD, Clardy CW, Bailey WW, et al: Complement activation and lung permeability during cardiopulmonary bypass. Ann Thorac Surg 1990; 50: 590-596
27. Martin LF, Var TC, Davied PK, et al: Intravascular plastic catheters: How they potentiate tumor necrosis factor release and exacerbate complications associated with sepsis. Arch Surg 1991; 126:1087-1093
28. Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; ii:355-357
29. Engelmann H, Aderua D, Rubinstein M, et al: A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264:11974-11980
30. Murray JC: Coagulation and cancer. Br J Cancer 1991; 64:422-424
31. Matsuura M, Galanos C: Induction of hypersensitivity to endotoxin and tumor necrosis factor by sublethal infection with Salmonella typhimurium. Infect Immun 1990; 58:935-937
32. Pinsky MR, Vincent J-L, Deviere J, et al: Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103:565-575